瑞芯微(603893.SH):潤科欣累計減持0.78%公司股份
格隆匯6月26日丨瑞芯微(603893.SH)公佈,公司於2025年6月26日收到公司持股5%以上股東廈門市潤科欣投資管理合夥企業(有限合夥)(以下簡稱“潤科欣”)的通知,其於2025年6月13日至2025年6月25日期間通過集中競價交易方式累計減持公司股份3,300,400股,佔公司股份總數的0.78%。另,2023年7月13日-2025年6月25日,因公司股權激勵計劃的限制性股票授予登記、股票期權的自主行權及部分限制性股票的回購註銷導致公司總股本發生變化,從而使潤科欣持股比例被動稀釋0.04%。綜上,本次權益變動後,潤科欣持有公司股份比例由6.76%變動爲5.94%,觸及1%刻度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.